DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Completed

Conditions: Axial Spondyloarthritis
Psoriatic Arthritis

Interventions: Drug: secukinumab

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 758

Registration Number: NCT05677542

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Completed

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Capmatinib

First Posted Date: 2023-01-09

Last Posted Date: 2023-01-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT05675683

Locations: 🇺🇸
18 Novartis Investigative Sites in the US, East Hanover, New Jersey, United States

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Phase 2

Active, not recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions: Drug: [177Lu]Lu-PSMA-617
Other: Best supportive/best standard of care (BS/BSOC)
Drug: 68Ga-PSMA-11

First Posted Date: 2023-01-04

Last Posted Date: 2025-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT05670106

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Phase 3

Active, not recruiting

Conditions: Macular Polypoidal Choroidal Vasculopathy (PCV)

Interventions: Drug: Brolucizumab 6mg

First Posted Date: 2022-12-28

Last Posted Date: 2025-04-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT05666804

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: MIJ821

First Posted Date: 2022-12-28

Last Posted Date: 2024-04-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT05666687

Locations: 🇬🇧
Novartis Investigative Site, Watford Road Harrow, United Kingdom

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions: Drug: ARDT
Drug: [177Lu]Lu-PSMA-617
Drug: [68Ga]Ga-PSMA-11
Other: Best supportive care

First Posted Date: 2022-12-20

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT05658003

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Completed

Conditions: Intraocular Inflammation
Retinal Vascular Occlusion

Interventions: Other: Brolucizumab

First Posted Date: 2022-12-20

Last Posted Date: 2022-12-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 198

Registration Number: NCT05657158

Locations: 🇨🇭
Novartis Investigative center, Basel, Switzerland

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Phase 3

Active, not recruiting

Conditions: Primary Immune Thrombocytopenia

Interventions: Biological: Ianalumab
Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2022-12-16

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 152

Registration Number: NCT05653219

Locations: 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸
University of Colorado Anschutz, Aurora, Colorado, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States

and more 9 locations

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Phase 3

Recruiting

Conditions: Primary Immune Thrombocytopenia (ITP)

Interventions: Biological: Ianalumab
Drug: Placebo
Drug: Corticosteroids

First Posted Date: 2022-12-16

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT05653349

Locations: 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸
Community Cancer Institute, Clovis, California, United States
🇺🇸
Compassionate Care Res Group Inc, Fountain Valley, California, United States

and more 24 locations

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Secukinumab

First Posted Date: 2022-12-14

Last Posted Date: 2023-04-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 163

Registration Number: NCT05650060

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy